Live Breaking News & Updates on வாழ்க்கை அறிவியல் ப்ர்யாக்டீஸ்

Stay updated with breaking news from வாழ்க்கை அறிவியல் ப்ர்யாக்டீஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Curative cell and gene therapies and healthcare system disruption


Curative cell and gene therapies and healthcare system disruption
SHARES
Introduction
Significant scientific advances have created a rich clinical research pipeline, with innovative and potentially curative cell and gene therapies already available (eg, Kymriah
® for acute lymphoblastic leukaemia, Luxturna
® for inherited retinal disease and Zolgensma
® for spinal muscular atrophy). Over the next 10 years, more of these therapies are expected to enter the market for other disease areas and larger patient populations. Potentially curative cell and gene therapies represent a key shift in patient care and will have considerable impact across the patient journey, affecting the healthcare system as we know it and the key stakeholders involved. Their launch is also met with significant debate over the uncertainty of outcomes’ durability and safety over the longer term; and the impact of treatment prices on affordability as more treatments enter the market. W ....

Charles River , United States , City Of , United Kingdom , Artes Haderi , Tanna Hillel , Lev Gerlovin , Rebecca Steele , Neil Turner , Taxus Cardium , Health Working Papers No , Life Sciences Practice , American Society Of Gene , Charles River Associates , Life Sciences Practice At Charles River Associates , General Practice , Family Practice , Federal Joint Committee , Consulting Associate , Cell Therapy , Disease Models , Heart Failure Gene , Trends Cardiovasc , One Time Gene Therapy For Coronary Heart , Advanced Chronic Heart Failure Surpasses , Primary Endpoint Events ,

Harnessing The Power Of AI In MS Diagnosis Monitoring And Treatment


Harnessing The Power Of AI In MS Diagnosis, Monitoring, And Treatment
By Andrew Thomson, Logan Wright, and Lev Gerlovin, Life Sciences Practice, CRA
Applications of artificial intelligence (AI) are rapidly expanding in healthcare, including the handling of administrative logistics at hospitals, assessment of patient health data, and analysis of novel molecules in drug discovery. A prime example of the future potential of AI is in revolutionizing the way we diagnose, monitor, and treat multiple sclerosis (MS), thereby advancing our understanding of the disease course. Today, MS continues to be a difficult disease to diagnose and treat because the underlying etiology remains unknown. Persistent challenges in the current treatment approach to MS include a lack of reliable biomarkers, making patient diagnosis, disease monitoring, and drug discovery challenging. To maximize the utility of AI in MS, drug developers and medtech manufacturers must strategically incorporate AI solu ....

Andrew Thomson , Lev Gerlovin , Axosim Nervesim , Logan Wright , Google Deepmind , Matia Sadat Borhani , Seyed Sajjad , Life Sciences Practice , Nature Publishing Group , Ai Technology Potential To Identify , Life Sciences , University Of California San Francisco , Disruption Factors , Learning Diagnostic Tools , Monitoring Disruption Factors , Track Patient Disease Progression , California San Francisco , Discovery Disruption Factors , Vitro Model , Identify Novel Biologic Drug Candidates , Critical Assessment , Structure Prediction , Rare Diseases , Matia Sadat , Vectors Machine Based Model , Multiple Sclerosis Using ,